Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

• Takeharu Yamanaka,
• Koji Yamamoto,
• Yasushi Honda,
• Kento Imajo,
• Yuji Ogawa,
• Takaomi Kessoku,
• Takashi Kobayashi,
• Anna Ozaki,
• Satoru Saito,
• Michihiro Iwaki,
• Yusuke Saigusa,
• Haruki Usuda,
• Koichiro Wada

Affiliations

Takeharu Yamanaka

4 Department of Biostatics, Yokohama City University, Yokohama, Japan

Koji Yamamoto

9 General Medicine, Sumitomo Hospital, Osaka, Japan

Yasushi Honda

professor emeritus

Kento Imajo

Department of Gastroenterology, Yokohama City University, Yokohama, Kanagawa, Japan

Yuji Ogawa

Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan

Takaomi Kessoku

Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan

Takashi Kobayashi

Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan

Anna Ozaki

Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan

Satoru Saito

Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan

Michihiro Iwaki

Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Yusuke Saigusa

Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Haruki Usuda

Department of Pharmacology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Shimane, Japan

Koichiro Wada

Department of Pharmacology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Shimane, Japan